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ABSTRACT
Diabetic nephropathy is the major cause of end-stage renal failure throughout the world
in both developed and developing countries. Diabetes affects all cell types of the kidney,
including endothelial cells, tubulointerstitial cells, podocytes and mesangial cells. During
the past decade, the importance of podocyte injury in the formation and progression of
diabetic nephropathy has been established and emphasized. However, recent findings
provide additional perspectives on pathogenesis of diabetic nephropathy. Glomerular
endothelial damage is already present in the normoalbuminuric stage of the disease
when podocyte injury starts. Genetic targeting of mice that cause endothelial injury leads
to accelerated diabetic nephropathy. Tubulointerstitial damage, previously considered to
be a secondary effect of glomerular protein leakage, was shown to have a primary signifi-
cance in the progression of diabetic nephropathy. Emerging evidence suggests that the
glomerular filtration barrier and tubulointerstitial compartment is a composite, dynamic
entity where any injury of one cell type spreads to other cell types, and leads to the
dysfunction of the whole apparatus. Accumulation of novel knowledge would provide a
better understanding of the pathogenesis of diabetic nephropathy, and might lead to a
development of a new therapeutic strategy for the disease.
INTRODUCTION
Diabetic nephropathy is a potentially fatal diabetic
vascular complication characterized by slowly increasing
proteinuria and a gradual decrease in renal function.
Diabetic nephropathy is the leading cause of end-stage
renal failure in Japan and Western countries, affecting
alarmingly large numbers of people worldwide1. In Japan,
diabetic nephropathy accounts for 44% of newly-induced
hemodialysis, and a governmental survey estimated that
there are approximately 100,000 hemodialysis patients.
The number of patients is increasing rapidly, making
diabetic nephropathy a critical social and economical
problem.
The pathogenesis of diabetic nephropathy has been intensely
investigated, and the roles of various mechanisms has been
established, and include the effect of high glucose, polyol
pathway activation, renin–angiotensin system activation, reac-
tive oxygen species (ROS), activation of the protein kinase C
pathway, increase of advanced glycation end-product (AGE)
and glomerular hyperﬁltration2,3. These changes lead to various
cellular responses, expression of secretory factors and extracellu-
lar matrices that ultimately result in disruption of the glomeru-
lar ﬁltration barrier, and histological changes including
mesangial expansion, nodular glomerular sclerosis and tubulo-
interstitial ﬁbrosis (Figure 1)4.
During the past decade, ‘podocentric’ experiments have
accumulated a huge amount of knowledge on the roles of
podocytes in diabetic nephropathy. In contrast, recent ﬁndings
have provided an additional perspective that other cell types
are also affected at very early stages of diabetic nephropathy
and contribute to the progression of the disease. To emphasize
this concept, the current review will highlight the emerging
roles of glomerular endothelial cells and tubulointerstitial cells
in the pathogenesis of diabetic nephropathy, and juxtapose
them to the roles of podocytes.Received 8 May 2014; accepted 15 May 2014
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GLOMERULAR ENDOTHELIAL CELLS
Glomerular endothelial cells are highly fenestrated, with 50- to
80-nm pores that go through the cytoplasm5. The luminal sur-
face of endothelial cells is covered by a thick layer of glycocalyx
that includes proteoglycans (PGs), such as syndecan, glypican,
perlecan and versican, as well as their glycosaminoglycan
(GAG) side chains, heparan sulfate and chondroitin sulfate6.
Endothelial GAGs maintain the negative charge of the endothe-
lial glycocalyx, and are believed to be a signiﬁcant component
of the glomerular charge barrier6.
Endothelial Cells are a Signiﬁcant Part of the Glomerular
Filtration Barrier
Because of the huge size of fenestration compared with that of
circulating proteins, such as albumin, it has been believed that
glomerular endothelial cells do not contribute to the ﬁltration
of macromolecules. However, emerging studies show its impor-
tance in the glomerular ﬁltration barrier. Digestion of GAGs
with heparanase, chondroitinase and hyaluronidase decrease the
thickness of the glycocalyx layer, and the negative charge den-
sity of the glomerular ﬁltration barrier, resulting in the increase
of the fractional clearance of albumin7,8. In addition, elusion of
non-covalently bound components of the endothelial glycocalyx
by infusion of hypersonic sodium chloride into the renal artery
leads to a 12-fold increase in the fractional clearance of
albumin without detectable change of the ultrastructure9. In
disease models, chronic infusion of hyaluronidase causes pro-
teinuria in apolipoprotein E (ApoE) knockout mice10, and Adri-
amycin injection largely decreases the thickness of the
glycocalyx and proteoglycan expression in the glomeruli11. These
experiments provide strong evidence that the endothelial glyco-
calyx forms a signiﬁcant part of the glomerular ﬁltration barrier.
Role of Endothelial Cells in Diabetic Nephropathy
Several diabetic animal models show reduced endothelial glyco-
calyx. In non-obese diabetic (NOD) mice, long-term diabetes
causes a threefold increase in the fractional clearance for nega-
tively charged albumin compared with controls. In contrast, the
fractional clearance for neutral Ficoll that has a similar size to
albumin is not increased. This change is accompanied by a
decrease in glycocalyx proteins including versican and deco-
rin12. Therefore, the authors concluded that the charge barrier,
rather than the size barrier, is affected in NOD mice glomeruli.
Disruption of the charge barrier before that of the size barrier
might show that endothelial damage occurs before podocyte/
glomerular basement membrane (GBM) damage in NOD mice.
In addition, staining for lectin that binds to hyaluronic acid
and heparin sulfates of the endothelial glycocalyx is attenuated
in streptozotocin (STZ)-induced diabetic rats13 and Zucker fatty
rats14.
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Figure 1 | Schematic diagram on pathogenesis of diabetic nephropathy. In diabetic conditions, high glucose, activation of the polyol pathway,
glomerular hyperfiltration, activation of the renin–angiotensin–aldosterone system (RAA), increase of advanced glycation end-product (AGE),
increased reactive oxygen species (ROS), activation of diacylglycerol (DAG)/protein kinase C (PKC) pathway and an increase in Tgfb lead to
abnormal cellular responses, such as overproduction of extracellular matrices and inflammation in the kidney. Diabetes also affects the production
of nitric oxide (NO), Angpt2 and glycocalyx in the glomerular endothelial cells, and leads to endothelial injury. In podocytes, reduced vascular
endothelial growth factor (VEGF) A expression increased mechanistic target of rapamycin (mTOR) signaling, and insulin resistance leads to podocyte
dysfunction resulting in podocyte detachment and apoptosis. Furthermore, recent findings show that tubulointerstitial fibrosis also plays significant
roles. These cell types are tightly connected together, and dysfunctions in one compartment can spread to other cell types.
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How about human beings? It has long been known that
endothelial injury, assessed by elevation of plasma von Wille-
brand factor, is seen in both type 1 and type 2 diabetic
patients15,16. An extensive study using state-of-the-art technol-
ogy showed that the volume of endothelial glycocalyx in the
total body and the thickness of the glycocalyx layer in retinal
and sublingual arteries are reduced in type 1 diabetic patients.
In that study, the decrease of endothelial glycocalyx was more
severe in the group with albuminuria17. A similar reduction of
the endothelial glycocalyx was also observed in type 2 diabetic
patients18. In addition, very important studies have shown mor-
phological abnormalities of renal glomerular endothelium in
diabetic patients. Toyoda et al.19 showed that the fraction of
fenestrated endothelium is reduced from 41% in controls to
32% in normo- and microalbuminuric patients, and further to
25% in macroalbuminuric patients with type 1 diabetes.
Recently, Weil et al.20 reported a similar decrease of fenestrated
area in type 2 diabetes patients (Figure 2). Interestingly, podo-
cyte detachment also starts in the normoalbuminuric stage and
correlates to albuminuria20. In that study, the endothelial fenes-
tration fraction correlated with the urinary albumin creatinine
ratio more closely compared with podocyte detachment.
Although podocyte detachment has been considered to be a
critical event in various types of glomerular diseases, including
diabetic nephropathy21, these studies clearly showed that endo-
thelial damage simultaneously occurs when podocytes are dam-
aged. This notion could raise a question against the concept
that podocyte injury is the primary event and endothelial dam-
age occurs as a secondary reaction22,23. These ﬁndings rather
support the concept that the glomerular ﬁltration barrier is a
composite multilayered structure, and injury in one layer might
spread to any other layers and affect the whole function of the
glomerular ﬁltration barrier.
Endothelial Dysfunction and Diabetic Nephropathy: Lessons
from Genetically Targeted Mice
Various cytokines and factors are secreted by/have effects on
endothelial cells to maintain the glomerular ﬁltration barrier.
Emerging evidence using genetically targeted mice prove their
importance in diabetic nephropathy.
Nitric Oxide
In diabetic animals and humans, bioavailability of the nitric
oxide (NO) is reduced24. In cultured endothelial cells, high glu-
cose inhibits endothelial NO synthase (eNOS) activity25. How-
ever, in type 2 diabetic patients, eNOS expression is increased
in kidney glomeruli by immunohistochemistry, and the increase
was correlated with more severe vascular complications26. Simi-
larly, protein expression of eNOS in STZ-induced diabetic rats
is increased in afferent arterioles and glomeruli27. In contrast,
eNOS required cofactors including tetrahydrobiopterin (BH4)
to produce NO. If eNOS is ‘uncoupled’, peroxynitrite
(ONOO–), a putative reactive oxygen species, is produced
instead of NO. In endothelial cells, high glucose results in a
(a)
(b)
Figure 2 | Endothelial injury is already present in the
normoalbuminuric stage. (a) The ultrastructure of glomerular filtration
barrier from a normal subject, note intact endothelial fenestration. (b)
Sample from a normoalbuminuric Pima Indian patient with type 2
diabetes showing intact podocyte foot processes, but normal
endothelial fenestrae are absent (arrows; adapted from Weil et al.20
with permission).
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uncoupling of eNOS, reduction of NO production and
increased superoxide production28. This uncoupling might
explain the discrepancy between elevated expression of eNOS
and reduced NO production in the diabetic condition.
The requirement of eNOS in the glomerular endothelium in
diabetes was examined using two diabetic animal models com-
bined with genetic deletion of eNOS. Both db/db and STZ mice
bred with eNOS knockout mice showed dramatic albuminuria,
increased glomerular basement membrane thickness, mesangial
expansion, and focal segmental and nodular sclerosis29,30. The
potential mechanism of the enhanced nephropathy was an
uncoupling of the vascular endothelial growth factor A (VEG-
FA)–eNOS axis, with enhanced VEGF expression and impaired
NO production, which led to excessive endothelial proliferation.
These phenotypes were at least partially mediated by intraglom-
erular hypertension, because lowering blood pressure rescues
the glomerular lesion in the diabetic eNOS deﬁcient mice31.
These results provide robust evidence that endothelial dysfunc-
tion results in enhancement of diabetic nephropathy and
suggest NO as a potential therapeutic target.
VEGFA
A large amount of VEGFA is produced by podocytes. The
secreted VEGFA go across the GBM and bind to kinase insert
domain protein receptor (Kdr; also known as VEGF receptor 2)
expressed on the endothelial cells. The VEGFA–Kdr axis is
essential for the formation and maintenance of the glomerular
ﬁltration barrier32,33. Podocyte-speciﬁc deletion of VEGFA leads
to impaired recruitment of endothelial cells into glomeruli, fail-
ure in formation of glomerular ﬁltration barrier and congenital
nephrotic syndrome33. Mice that carry haploinsufﬁcient VEG-
FA allele in podocytes show an endothelial swelling and loss of
fenestration in glomeruli known as endotheliosis – a feature
seen in thrombotic microangiopathies (TMA)33. Overexpression
of VEGFA in podocytes leads to a collapse of the glomerular
tuft33. In addition, patients on anti-VEGF therapy sometimes
develop proteinuria as a result of TMA of the glomeruli34.
Indeed, deletion of VEGFA alleles from adult mice podocytes
results in TMA34.
The role of VEGFA in diabetic nephropathy has been a con-
troversy. An increase of VEGFA expression was shown in the
glomeruli and tubulointerstitium in STZ diabetic rats and in
type 2 diabetic mice35–37. As VEGFA is a potent stimulator that
destabilizes endothelial cells and induces vascular permeability,
some investigators attempted to block VEGFA signaling to treat
diabetic nephropathy in mice38,39. In db/db mice, an inhibitor
for tyrosine kinase of Kdr reduced urinary albumin excretion
(UAE)40,41. In Zucker diabetic rats, the neutralizing antibody
for VEGF reduced glomerular hypertrophy, but did not
improve UAE40. Therefore, these reports appear to support the
notion that VEGF worsens diabetic nephropathy.
However, reports on VEGFA expression in human diabetic
nephropathy are inconsistent. Hohenstein et al.42 reported
enhanced VEGFA expression in glomeruli of type 2 diabetes
patients by immunostaining. In contrast, Baelde et al.43 showed
reduction of Vegfa messenger ribonucleic acid expression in
human type 2 diabetic glomeruli by Affymetrix microarray43.
Several additional reports showed that Vegfa expression
was decreased in both the glomeruli and tubulointerstitium, and
was correlated with reduced renal microvascular density, tubular
epithelial atrophy, mesangial expansion and proteinuria44,45.
These results rather support the notion that VEGF is protective.
Recently, two genetic mice models shed a new light onto this
controversy. Veron et al.46 produced a mouse model that car-
ries podocyte-speciﬁc inducible overexpression of Vegf164, and
rendered the mice diabetic by STZ injection. The results
showed accelerated nephropathy with Kimmelstiel–Wilson like
nodular glomerulosclerosis and massive proteinuria46. In con-
trast, Sivaskandarajah et al.47 showed that inducible deletion of
VEGFA in adult podocytes results in severe enhancement of
diabetic nephropathy using a STZ-induced mice model. In that
report, the diabetic mutant showed severe glomerulosclerosis,
enhanced proteinuria and increased apoptosis in the kidneys47.
These results clearly show that the levels of VEGFA in the
glomeruli require ‘ﬁne tuning’, and either overdose or suppres-
sion could result in exacerbation of diabetic nephropathy. This
tight and subtle regulation is similar to that of VEGFA in
glomerular development.
Angiopoietins
Another family of angiogenic factors required for maintenance
of glomerular endothelial cells is angiopoietin–Tek signaling.
Angiopoietin 1 (Angpt1) and angiopoietin 2 (Angpt2) are both
ligands to Tek tyrosine kinase (Tek/Tie-2)48,49. Angiopoietin 1
binds to the Tek receptor expressed on endothelial cells, and
cause its tyrosine phosphorylation, but Angpt2 works as an
antagonist while not activating any intracellular signaling. How-
ever, some data suggest that Angpt2 activates phosphorylation
of Tek in certain conditions50. Angpt1 is believed to stabilize
the blood vessel, reduce vascular permeability and support the
survival of endothelial cells. Angpt1 conventional knockout
mice die at embryonic day 12.549 and Angpt2 knockout is also
perinatal lethal51.
Recent analysis using conditional alleles showed critical roles
of Angpt1 in glomeruli. Jeansson et al. showed that deletion of
Angpt1 at embryonic day 10.5 resulted in abnormal glomerular
development with a single capillary loop without mesangial
migration that is reminiscent to the phenotype of Pdgfb/Pdgfrb
mutants52,53. In contrast, loss of the Angpt1 allele at e13.5 does
not cause any phenotype, showing that Angpt1 is only required
when the vasculature is undergoing dynamic remodeling.
The role of angiopoietins in diabetes has been shown by sev-
eral reports. In diabetic patients, Angpt2 expression is
increased54. On the other hand, diabetic animal models show a
decrease of Angpt1 and increase of Angpt2. Furthermore, STZ-
induced diabetic mice with whole-body or glomerular-speciﬁc
Angpt1 deletion develop increased urinary albumin excretion,
severe mesangial expansion, glomerular sclerosis and early
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mortality53. A study using db/db mice showed that treatment
with recombinant adenovirus-expressing cartilage oligomeric
matrix protein (COMP)-Ang-1, a potent Angpt-1 variant,
resulted in improvement in diabetic renal damage55. Recently,
STZ diabetic mice with podocyte-speciﬁc overexpression of
Angpt1 also showed a similar protective effect on diabetic
nephropathy56. Taken together, the Angpt1–Tek axis plays an
important protective role in glomerular endothelial cell function
in the diabetic condition. Drugs that target Angpt1 and its
downstream molecules might provide potentially useful thera-
peutic strategies.
TUBULOINTERSTITIAL CELLS
Although it has been widely accepted that glomerular injury is
the main component of diabetic nephropathy, plenty of evi-
dence has shown that tubulointerstitial changes are present and
are involved in its progression57. Tubulointerstitium includes
the tubular system, interstitial cells and vascular system, and
accounts for as much as 90% of kidney volume58.
Histological Abnormality of Tubulointerstitium Correlates with
Progression of Diabetic Nephropathy
Histologically, early diabetic kidneys show tubular hypertrophy,
thickening of the tubular basement membrane and interstitial
inﬂammation with mononuclear cell inﬁltration59. When it pro-
gresses, they show tubular atrophy and tubulointerstitial ﬁbrosis.
Interestingly, tubulointerstitial expansion closely correlates with
elevation of serum creatinine in both type 1 and type 2 diabe-
tes60–62. Taft et al.63 followed 47 patients with diabetes for
4 years, and carried out renal biopsies at the beginning and the
end of the study. The results showed that cortical tubulointersti-
tial ﬁbrosis more closely correlated to the decrease of creatinine
clearance than glomerular changes63. This association seems to
be weaker in the microalbuminuric stage64, suggesting that tub-
ulointerstitial ﬁbrosis is a good determinant of moderate-to-
severe renal injury rather than early diabetic nephropathy59.
In addition, abnormalities in glomerulotubular junctions have
been reported in diabetic kidneys. A study on renal biopsy
samples of type 1 diabetes patients showed that 4% of glome-
ruli from microalbuminuric patients show some glomerulotubu-
lar junctional abnormalities, including connections of glomeruli
to atrophic tubules. Furthermore, in the macroalbuminuric
stage, 71% of glomeruli showed glomerulotubular junction
abnormalities, including 8% glomeruli without any tubule con-
nected (atubular glomeruli)65,66. Type 2 diabetic glomeruli also
show atubular glomeruli and connection to atrophic tubules
from the stage of microalbuminuria67. These data suggest that,
even though tubulointerstitial changes are dominantly seen in
the advanced stage, subtle abnormality is already present in the
microalbuminuric time-point.
Increase of Tubular Markers in Urine of Early Diabetic Patients
Data of urinary biomarker also show that tubular damage starts
at an early stage of diabetic nephropathy. Studies on type 1
diabetic children showed that urinary N-acetyl-b-D-glucosa-
minidase (NAG) is increased in diabetes patients compared
with normal controls, and is correlated with urinary albumin
excretion and glycemic control. This increase was already seen
in the microalbuminuric stage68,69. Intriguingly, within microal-
buminuric type 1 diabetic patients, a group that shows low lev-
els of urinary NAG and kidney injury molecule 1 (KIM-1)
tends to show regression of albuminuria after 2 years, suggest-
ing that tubular dysfunction is a critical component of the early
course of diabetic nephropathy69.
Does Tubulointerstitial Change Affect Glomerular Structure
and Function–Tubuloglomerular Feedback?
It has been considered that the glomeruli is the primary site of
injury, and the tubulointerstitial change is a secondary reaction
to elevated intratubular protein as a result of glomerular leak-
age. Recent studies suggested that tubular changes could lead to
alteration in glomerular structure and function.
Using genetically modiﬁed mice, VEGFA was overexpressed
in renal tubular cells on administration of doxycyline. The
mutant mice showed an interstitial ﬁbrosis and tubular cysts
with dense network of peritubular capillaries. The mice did not
show signiﬁcant proteinuria; however, they developed glomeru-
lar changes including marked mesangial expansion similar to
that seen in diabetic nephropathy. The authors observed down-
regulation of VEGFA expression in podocytes, and concluded
that tubular overproduction of VEGFA resulted in suppression
of VEGFA in podocytes that led to interference of cross-talk
between podocytes and the endocapillary compartment
(Figure 3)70.
Another study also provides evidence for tubuloglomerular
feedback. Deletion of sirtuin 1 (Sirt1), a NAD+ regulated
deacetylase, speciﬁcally in tubules leads to increased albumin-
uria and effacement of podocyte foot processes. Additionally,
STZ-induced diabetes aggravated the nephropathy of tubule-
speciﬁc Sirt1 knockout mice. Furthermore, overexpression of
Sirt1 in tubules protected the mice from the glomerular ultra-
structural changes and albuminuria in STZ mice. In human
diabetic nephropathy with proteinuria, Sirt1 was downregulated
and Claudin1 was upregulated. These results suggest that Sirt1
in proximal tubules protects against diabetic nephropathy and
inﬂuence podocyte function71. Taken together, these experi-
ments clearly show that tubulointerstitial change can affect glo-
merular structure and function.
Epithelial to Mesenchymal Transformation in Diabetic
Nephropathy
Epithelial to mesenchymal transformation (EMT) is a cellular
process through which epithelial cells undergo ‘de-differentia-
tion’; lose epithelial characteristics; express mesenchymal mark-
ers, such as alpha-smooth muscle actin, desmin and vimentin;
and acquire a matrix-producing ﬁbroblast-like phenotype. A
study using genetically tagged proximal tubules showed that up
to 36% of the interstitial ﬁbroblasts were derived from proximal
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tubules in a unilateral ureter obstruction mouse model72.
A recent analysis reported that 35% of the myoﬁbroblasts were
derived from bone marrow, 10% from endothelial cells and
5% from tubular cells through an EMT program in a unilateral
ureter obstruction model73,74. In diabetic nephropathy, EMT-
like changes of the tubules, such as upregulation of vimentin
and decrease of E-cadherin, have been observed both in vitro
and in vivo75,76. In addition, tubular expressions of mesenchy-
mal markers are also shown in renal biopsy samples from
human diabetic nephropathy77. In contrast, however,
overexpression of transforming growth factor beta (Tgfb) in
tubular cells, a multifunctional cytokine that is believed to be
the key mediator of EMT, resulted in total decomposition of
tubular cells and ﬁbrosis, but not mesenchymal transformation
of tubular cells78. Therefore, there is no solid evidence that
tubular cells transform into matrix-producing interstitial ﬁbro-
blasts in diabetic nephropathy. In terms of endothelial to mes-
enchymal transformation, Li et al.79 carried out genetic tag
experiments using Tie2-Cre mice, and showed that infusion of
AGE to mice resulted in ﬁbroblasts derived from endothelial
cells79.
PODOCYTES
Morphology of Podocytes
Podocytes are terminally differentiated cells that wrap the glo-
merular capillary loops from outside, providing physical sup-
port and secretary cytokines. They develop microtubule-based
thick primary foot processes and ﬁne actin-based secondary
foot processes that interdigitate each other. The foot processes
from the neighboring podocytes are connected with each other
by a specialized intercellular junction called a slit diaphragm
(SD). SD consists of proteins including nephrin, podocin, Cd2-
ap and actin-binding protein alpha-actinin 4. The mutations of
these proteins cause focal and segmental glomerulosclerosis in
mice and humans, thus SD is considered to be essential in
macromolecular ﬁltration80.
Diabetic Nephropathy and Podocytes
The early key events in diabetic nephropathy include loss of
podocytes in glomeruli. A landmark study was carried out by
Pagtalunan et al.81, and showed that the number of podocytes
per glomeruli were reduced in renal biopsies from Pima Indian
type 2 diabetes patients with macroproteinuria. The loss of
podocytes was correlated with the ﬂattening of podocyte
foot processes81. Subsequent analysis showed that the decrease
of podocyte number is a good predictor of progression of
albuminuria82. Similar ﬁndings are also reported on the
nephropathy of type 1 diabetic patients19,83.
The mechanism of podocyte loss is considered to be detach-
ment and apoptosis. Podocyte apoptosis is observed in many
animal diabetic models including Akita mice, db/db84 mice and
STZ induced rats85, and could at least partially be mediated by
an increase of Tgfb, Smad786, AGE87, angiotensin II88 and
reactive oxygen species84. In human type 2 diabetic kidneys,
apoptosis was seen in both tubular and glomerular compart-
ments, some was obviously in podocytes89. In contrast, under
diabetic conditions, some podocytes detach from the GBM
and fall into the urine. The detached ‘urinary’ podocytes are
viable and can propagate ex vivo90. Indeed, patients of type 2
diabetes show urinary excretion of podocytes, and it worsens
as the disease progresses from normoalbiminuria, microalbu-
minuria and to macroalbuminuria91. Interestingly, the urinary
podocyte detachment can be reduced by administration of
hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors92.
(a)
(b)
Figure 3 | Genetic overexpression of vascular endothelial growth
factor A (VEGFA) in tubules results in glomerular disease. (a) A
glomerulus from a control mouse. (b) A glomerulus from a tubular-
specific VEGFA overexpression mouse that shows dilated capillaries at
the periphery and nodule-like mesangial expansion, showing that
tubular dysfunction results in glomerular disease (reproduced from
Hakroush et al.70 with permission).
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Factors Involved in Podocyte Function in Diabetic
Nephropathy
Proteins of Slit Diaphragm
Nephrin is a 180-kDa transmembrane protein that belongs to
the immunoglobulin superfamily. In 1998, Karl Triggvasson
et al.93 group identiﬁed the nephrin (NPHS1) gene, and showed
that its mutations caused the congenital nephrotic syndrome of
the Finnish type. The nephrin cytoplasmic tail includes three
tyrosine-aspartic acid-x-valine (YDxV) residues. These residues
are phosphorylated by Src family kinases, recruit SH2/SH3 con-
taining Nck adaptor proteins resulting in reorganization of
actin cytoskelton. Deletion of Nck1/2 in podocytes leads to
massive congenital proteinuria94,95. Many reports have shown
downregulation of nephrin in diabetic nephropathy in rodent
models and human patients96–98. Some reports suggest that
the decrease of nephrin is partially mediated by the renin–
angiotensin system, AGE and protein kinase C pathway98–101.
In contrast, there are also several reports showing upregulation
of nephrin expression in mice diabetic kidneys41,102. The cause
of this diversity is still unknown, but could be a difference of
disease stages. In addition, other slit diaphragm proteins, such
as podocin and synaptpodin, are also signiﬁcantly reduced in
human diabetic nephropathy103.
Insulin Signaling
Podocytes express insulin receptor and increase their glucose
uptake on insulin stimulation104. In addition, knockdown of
nephrin in podocytes attenuates insulin-dependent glucose
uptake in podocytes, showing that nephrin is required for insulin
function in podocytes105. Recently, a study on a genetic mouse
model that lacks insulin receptor in podcytes was reported. The
mice showed massive proteinuria and histological abnormality
similar to diabetic nephropathy. In addition, in vitro studies
using an immortalized human podocyte cell line suggest that
insulin sends signals through mitogen-activated protein kinase
(MAPK) and phosphoinositide 3-kinase (PI3K), and regulates
actin cytoskeleton remodeling in podocytes106. These studies
show that local insulin resistance affects podocyte function and
leads to progression of diabetic nephropathy, thus demonstrating
the importance of the therapy that increases insulin sensitivity in
podocytes.
mTor Signaling
The mechanistic target of rapamycin (mTor) is a ubiquitously
expressed serine-threonine kinase. mTor binds to regulatory-
associated protein of mTOR (Rptor), or Rptor independent
companion of mTor (Rictor), and forms mTORC1 and
mTORC2, respectively107. mTORC1 is activated by amino
acids, stress, oxygen and growth factors, and regulates protein
translation, ribosomal biogenesis, cell growth and autophagy.
mTORC2 responds to growth factors, and regulates cell survival,
growth, metabolism and cytoskeletal rearrangement107. Rapamy-
cin acutely suppresses mTORC1 function108; however, in certain
contexts, it also inhibits mTORC2109. Interestingly, organ
transplant patients using rapamycin sometimes develop
proteinuria, suggesting the importance of mTor signaling in
glomeruli108. Indeed, mice studies showed that the mTor path-
way is essential for podocyte function. Deletion of mTor or
Rptor speciﬁcally from podocytes leads to massive proteinuria
and renal failure110,111.
In contrast, mTor activity was increased in renal biopsy
samples of diabetic patients and in diabetic db/db mice111,112.
Activation of mTORC1 by deletion of its suppressor, Tsc1, in
podocytes results in proteinuria, podocyte loss, mesangial
expansion and thickening of glomerular basement mem-
brane112. Furthermore, haploinsufﬁciency of Rptor protected
mice from diabetic nephropathy in STZ mice and db/db mice,
showing a decrease in urinary albumin excretion and mesangial
expansion111,112. These results show the critical roles of mTor
signaling in diabetic nephropathy, and that either overactivation
or elimination of the mTor pathway leads to podocyte dysfunc-
tion and glomerular disease. Recent analysis showed that podo-
cyte-speciﬁc ablation of Rictor or Akt2, a potent target of
mTORC2, results in accelerated nephropathy induced by
heminephrectomy, showing that mTORC2 is also involved in
progression of chronic kidney disease (CKD)113.
Notch Signaling
The Notch pathway regulates cell proliferation, differentiation,
cell fate speciﬁcation and organ development, and is conserved
in all metazoans114. Notch is a transmembrane receptor that
binds to cell surface ligands, such as Delta-like or Jagged, on
neighboring cells. On interaction of these ligands, Notch intra-
cellular domain (NICD) is cleaved by gamma-secretase, and
then NICD translocates to the nucleus where it forms
transcriptional complexes with deoxyribonucleic acid (DNA)
binding proteins including RBPj, CBF1 and Su114.
Although the importance of the Notch pathway has been
well documented in renal development, it is mostly silenced in
adult normal kidneys115. However, NICD is increased in podo-
cytes of human diabetic nephropathy and focal segmental
glomerulosclerosis, and in db/db mice. Conditional overexpres-
sion of NICD in podocytes resulted in proteinuria and glomer-
ulosclerosis. In addition, deletion of RBPj, an essential
transcriptional partner of NICD, or administration of gamma-
secretase inhibitor, protected rats from proteinuric renal models
including diabetic nephropathy115. The Notch pathway might
mediate high glucose-induced apoptosis in podocytes116,117.
Wnt/beta-Catenin Signaling
Wnts are a family of highly-conserved secreted glycoproteins
that regulate cell proliferation, cell fate determination, organo-
genesis and tumorgenesis. Beta-catenin is the central compo-
nent of the canonical Wnt pathway. On binding of Wnts to
their receptor, Frizzled, a series of downstream signalings
including Dishvelled, Axin, adenomatous polyposis coli
(APC) and glycogen synthase-3beta (GSK-3beta) are activated,
and eventually lead to dephosphorylation of beta-catenin.
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Dephosphorylated beta-catenin escapes the ubiquitin-mediated
degradation, then the stabilized beta-catenin translocates to the
nucleus where it binds to DNA and regulates transcription of
various target genes.
Wnt beta-catenin signaling is activated in podocytes of dia-
betic nephropathy in humans and STZ-induced diabetic
mice118,119. Pharmacological activation118, as well as podocyte-
speciﬁc stabilization of beta-catenin, leads to albuminuria119.
Interestingly, deletion of beta-catenin in podocytes and expres-
sion of Wnt inhibitor Dickkopf-related protein 1 (Dkk1) result
in enhancement of diabetic nephropathy induced by STZ119,
suggesting that both hypo- and hyperactivation of the beta-cate-
nin pathway promotes proteinuric diseases. In vitro studies
showed that Wnt/beta-catenin signaling regulates podocyte
motility, adhesion, apoptosis and expression of podocyte differ-
entiation markers including nephrin119. Interestingly, beta-cate-
nin is a key molecule that regulates the cell fate determination
when podocytes differentiate from renal vesicles120.
Tgfb
Many reports show that Tgfb is a central factor that contributes
to the progression of glomerulosclerosis. Increased expression
of Tgfb1 is observed in human diabetic kidneys at early and
late stages of nephropathy, and the expression of Tgfb is corre-
lated with glycemic control121,122. In db/db mice, elevation of
Tgfb, its receptor Tgf beta receptor 2 (Tgfbr2) and nuclear
translocation of Smad3, a main signaling transducer of Tgfb
signaling, were observed123. Tgfb level was elevated in the
glomeruli of STZ-induced diabetic rats by micropuncture124. In
addition, overexpression of Tgfb in hepatocytes results in multi-
ple organ phenotype including glomerulonephritis and renal
ﬁbrosis125. Recently, overexpression of Tgfb receptor 1 speciﬁ-
cally in podocytes resulted in massive glomerulosclerosis126.
Interestingly, this phenotype was mediated by Endothelin1
release by podocytes, which leads to mitochondrial oxidative
stress in adjacent endothelial cells in a paracrine manner, thus
emphasizing the importance of cross-talk between podocytes
and endothelial cells.
As mentioned earlier, Tgfb is reported to induce podocyte
apoptosis through the P38-MAPK pathway86. Smad7 is one of
the downstream targets of Tgfb signaling, and is also known as
a potent inhibitor of the classical Smad signaling pathway,
forming a negative feedback. Smad7 knockout mice show exac-
erbated diabetic nephropathy with increased albuminuria,
enhanced renal ﬁbrosis and increased expressions of inﬂamma-
tory factors. In the diabetic Smad7 knockout kidneys, both the
Tgfb–Smad pathway and nuclear factor-kappa B pathway are
activated. Overexpression of Smad7 by gene transfer speciﬁcally
to kidneys attenuated microalbuminuria127. Although Smad7 is
reported to induce podocyte apoptosis86, these data suggest that
Smad7 plays a protective role in diabetic nephropathy, highly
likely through suppression of Tgfb signaling pathways.
In the immortalized podocyte cell line, Tgfb decreased
podocyte markers, such as nephrin and Zo-1, and increased
mesenchymal markers, including alpha smooth muscle actin
and vimentin, showing that Tgfb induces de-differentiation in
podocytes similar to epithelial mesenchymal transformation128.
In addition, it has been shown that Tgfb increases the expres-
sion of extracellular matrices including ﬁbronectin and type IV
collagen in podocytes, and contributes to the thickening of
GBM129,130.
Soluble Flt1
Soluble fms-related tyrosine kinase 1 (sFlt1) is an alternatively
spliced soluble form of VEGF receptor 1 (VEGFR-1)/Flt-1, and
works as a decoy ligand to Kdr. An increase of sFlt1 using ade-
novirus results in a marked decrease of endothelial fenestrae in
mice glomeruli131. sFlt blood levels are higher in pre-eclampsia
patients, and injection of sFlt1 to pregnant rats causes hyper-
tension and proteinuria132. A recent report showed a surprising
additional function of sFlt1 on non-endothelial cells through
Kdr-independent mechanisms. Deletion of Flt1 in podocytes
leads to reorganization of their cytoskeleton, massive protein-
uria and renal failure. The allele that lacks the intracellular
kinase domain of Flt1 rescues this proteinuric phenotype, sug-
gesting that full-length protein is not critically required. The
authors showed that sFlt binds to the lipid microdomain on
the podocyte surface, and promote cellular adhesion and actin
reorganization133. Interestingly, mice with overexpression of
sFlt1 in podcytes were protected from STZ-induced changes in
glomeruli. Transgenic diabetic mice show a decrease in urinary
albumin excretion, mesangial expansion, podocyte foot pro-
cesses fusion and glomerular basement membrane thicken-
ing134. These results show an interesting autocrine function of
sFlt1 that protects podocytes in addition to its role as a decoy
on endothelial VEGFA signaling. However, systemic overex-
pression of sFlt1 will not be useful, because intramuscular injec-
tion of adeno-associated virus 1 encoding human soluble Flt1
resulted in improvement in podocyte injury, but exacerbated
tubulointerstitial damage, showing a conﬂicting effect of sFlt1
in podocytes and interstitial compartment135.
Rho GTPases
Rho guanosine triphosphatases (GTPases) are known as master
regulators of actin cytoskeleton. The classical members of this
family are Rho, Rac1 and Cdc42. Activation of Cdc42 leads to
ﬁllipodia formation, Rac1 promotes lamellipodia formation and
RhoA mainly regulates formation of stress ﬁbers136. Many
reports suggested its importance in podocyte biology. Podocyte-
speciﬁc deletion of Cdc42 leads to a congenital nephrotic syn-
drome and renal failure with defect in actin polymerization at
intracellular domain of nephrin137, whereas the other two Rho
guanosine triphosphatases did not show any proteinuria when
deleted in podocytes. Activation of RhoA in podocytes results
in focal segmental glomerulosclerosis138. It has been shown that
RhoA is activated in the renal cortex of diabetic db/db mice139.
Several trials have been carried out to suppress RhoA in dia-
betic rodent models. Administration of Fasudil, a Rho-kinase
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inhibitor, resulted in attenuation of urinary albumin excretion,
ultrastructural chances of glomerular ﬁltration barrier and me-
sangial expansion in db/db mice139. A similar protective effect
was also observed in STZ-induced diabetic mice and rats140–142.
These effects included suppression of Tgfb1 and connective
tissue growth factor, and hypoxia-inducible factor 1 alpha
signaling141,142.
CONCLUSION
Diabetic nephropathy affects many cellular functions, some of
them are common across cell types and some are cell-type spe-
ciﬁc. Recent studies showed distinct roles of each compartment,
and factors that are required for cross-talk between cell types.
An accumulation of a better understanding on the pathogenesis
of diabetic nephropathy would provide a novel opportunity for
the development of a new therapeutic strategy.
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